Poolbeg Pharma granted US patent for influenza treatment

(Alliance News) - Poolbeg Pharma PLC on Wednesday announced its immunomodulator I patent has been granted in the US.

The London-based clinical stage biopharmaceutical company targeting diseases with a high unmet medical need said the patent covered Poolbeg's POLB 001 asset and other p38 mitogen-activated protein kinase inhibitors.

POLB 001 is a treatment for patients at risk of severe influenza after an immune response has been triggered, as well as a treatment for hypercytokinemia, or cytokine storm, a characteristic of severe influenza that develops when the immune system responds to infection or immunotherapy drugs more aggressively than it should.

Chief Executive Officer Jeremy Skillington said: "This award by the US patent office further strengthens the [intellectual property] for our lead development candidate, POLB 001. Strong IP is the foundation of value creation in biopharma, and with each new patent, we not only protect our asset but also increase the commercial appeal of POLB 001 to prospective partners.

"We are excited by the potential of POLB 001 to address critical unmet medical needs and we remain focused on high value programmes and partnerships to develop and commercialise our assets."

Shares in Poolbeg Pharma closed 3.8% lower at 7.60 pence each in London on Wednesday.

By Emily Parsons, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Poolbeg Pharma